Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|76|3|151-156

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.3, 2009-01, pp. : 151-156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials

By  

Oncology, Vol. 81, Iss. 2, 2011-10 ,pp. : 135-140

Karger

Access to resources Recommend Favorite

Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-05 ,pp. : 357-362

Karger

Access to resources Recommend Favorite

Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 72, Iss. 1-2, 2007-11 ,pp. : 58-63

Karger

Access to resources Recommend Favorite

Multicenter Phase I Study of Irinotecan plus Raltitrexed in Patients with 5-Fluorouracil-Refractory Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 42-47

Karger

Access to resources Recommend Favorite

Gefitinib in Combination with Capecitabine as Second-Line Therapy in Patients with Advanced Colorectal Cancer (aCRC): A Phase I/II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

By  

Oncology Research and Treatment, Vol. 33, Iss. 3, 2010-02 ,pp. : 89-93

Karger

Access to resources Recommend Favorite